Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease
Open Access
- 26 March 2021
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 90 (1) , 52-61
Abstract
Objective: The aim was to demonstrate that continuous s.c. infusion of a soluble levodopa (LD)/carbidopa (CD) phosphate prodrug combination effectively delivers stable LD exposure via a minimally invasive and convenient mode and has the potential to treat Parkinson's disease (PD) patients who are not well controlled on oral medication.Methods: Foslevodopa and foscarbidopa were prepared and the equilibrium solubility and chemical stability examined in aqueous media with different values of pH. Solutions of foslevodopa/foscarbidopa (ratios ranging from 4:1 to 20:1) were prepared by dissolving pH‐adjusted lyophilized materials in water and infused s.c. in healthy volunteers for ≤72 hours. Frequent blood samples were collected to measure LD and CD exposure, and safety was monitored throughout the study.Results: Foslevodopa/foscarbidopa (ABBV‐951) demonstrates high water solubility and excellent chemical stability near physiological pH, enabling continuous s.c. infusion therapy. After s.c. infusion, a stable LD pharmacokinetic (PK) profile was maintained for ≤72 hours, and the infusion was well tolerated.Interpretation: Preparation of foslevodopa and foscarbidopa enables preclinical and clinical PK, safety, and tolerability studies in support of their advancement for the treatment of PD. In phase 1 clinical trials, foslevodopa/foscarbidopa demonstrates consistent and stable LD plasma exposure, supporting further studies of this treatment as a potentially transformational option for those suffering from PD. ANN NEUROL 2021;90:52–61Keywords
Funding Information
- AbbVie (N/A)
This publication has 21 references indexed in Scilit:
- Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administrationActa Pharmacologica Sinica, 2015
- Parkinson's diseaseThe Lancet, 2015
- 24 h Levodopa–carbidopa intestinal gel may reduce falls and “unresponsive” freezing of gait in Parkinson's diseaseParkinsonism & Related Disorders, 2015
- Levodopa‐carbidopa intestinal gel in advanced Parkinson's disease: Final 12‐month, open‐label resultsMovement Disorders, 2014
- Novel formulations and modes of delivery of levodopaMovement Disorders, 2014
- Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease PatientsThe AAPS Journal, 2012
- Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's diseaseMovement Disorders, 2011
- Oxidation of carbidopa by tyrosinase and its effect on murine melanomaBioorganic & Medicinal Chemistry Letters, 2009
- An Essay on the Shaking PalsyThe Journal of Neuropsychiatry and Clinical Neurosciences, 2002
- Potent Decarboxylase Inhibitors. Analogs of Methyldopa1Journal of Medicinal Chemistry, 1963